Article

Good outcomes possible in eyes with PXF

Pseudoexfoliation (PXF) is a common disorder that mandates special attention when cataract surgery is indicated.

Key Points

"We need to be aware of PXF, and we need to be wary of it because intra- and postoperative complications of cataract surgery are greater in eyes with this disorder," said Dr. Shingleton, assistant clinical professor, Harvard Medical School, and clinical instructor of ophthalmology, Tufts University School of Medicine, Boston.

Dr. Shingleton said he considers PXF the most common problematic issue in his practice, which embraces both cataract and glaucoma.

Patients in the group had a mean age of 75 years and were about three-fourths females. Follow-up ranged from 1 day to 19 years, with a mean exceeding 3 years.

Dr. Shingleton presented retrospective analyses comparing outcomes in 1) fellow eyes of patients with unilateral PXF who underwent bilateral phacoemul-sification and 2) eyes with PXF, and without glaucoma. He also presented the results from eyes with PXF and glaucoma undergoing combined surgery.

Overall, the results showed that cataract surgery in PXF eyes with or without glaucoma is associated with good visual outcomes and long-term IOP control, and combined surgery results in even greater IOP reduction. The analyses also highlighted the fact that eyes with PXF are at increased risk for intraoperative and postoperative complications that are directly related to zonular weakness, however.

Phaco in fellow eyes

"It is well documented that IOP decreases after cataract surgery in normal eyes, but the magnitude of the decrease in the eyes with PXF was even greater than that," Dr. Shingleton said. "The fellow eyes do not do as well as the normal [eyes] and may be thought of as a hybrid between normal and eyes with PXF."

Phaco in eyes with PXF

This comparison included 217 eyes with glaucoma and 690 eyes without glaucoma. Both groups exhibited a reduction in IOP after cataract surgery that was sustained among eyes followed beyond 5 years. The change from baseline was greater in the eyes with glaucoma, although glaucoma medication use remained fairly stable, Dr. Shingleton noted.

Especially notable from this analysis was the finding that IOP spikes occurred fairly frequently on the first day after surgery in both the eyes with and without glaucoma (38% and 17%, respectively).

"These events were more common than I would have expected and occurred despite effective removal of viscoelastic and routine treatment with a topical beta-blocker and alpha-agonist or an oral carbonic anhydrase inhibitor," Dr. Shingleton said. "The message is to beware of IOP spikes after phaco in patients with PXF."

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times)  ASCRS 2025: Joaquin De Rojas, MD, leverages machine learning model to predict arcuate outcomes
Shehzad Batliwala, DO, aka Dr. Shehz, discussed humanitarian ophthalmology and performing refractive surgery in low-resource, high-risk areas at the ASCRS Foundation Symposium.
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
© 2025 MJH Life Sciences

All rights reserved.